Five UK firms have been slapped with a combined £35 million (US$47 million) fine from the competition watchdog for illegally driving up the price of an anti-nausea drug used by the National Health Service (NHS), reported Bloomberg.
The Competitions and Markets Authority (CMA) stated the price the NHS paid for prochlorperazine surged from £6.49 to £51.68 per pack of 50 tablets between 2013 and 2017.
Prochlorperazine is used to treat nausea, dizziness, and migraines. The price rise for the drug represented an increase of 700%. Annual costs for the drug soared from around £2.7 million to about £7.5 million, even though the number of packs dispensed fell.
The CMA stated Alliance Pharmaceuticals, Lexon, Medreich, and the former and current owners of Focus broke the law by striking an illegal arrangement to limit supply of the tablets. Focus is now owned by Advanz, and was previously owned by the private equity firm Cinven.
Under the arrangement, Alliance Pharmaceuticals appointed Focus as its distributor, and Lexon and Medreich were paid a share of the profits that Focus earned by selling Alliance’s product. In return, Lexon and Medreich agreed not to compete in the supply of these prochlorperazine tablets in the UK.
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Redfin Settles $9.2M Commission Inflation Lawsuits
May 7, 2024 by
CPI
DOJ Supports Colorado’s Efforts to Block Kroger-Albertsons Merger
May 7, 2024 by
CPI
Japan Considers Regulation of AI Developers
May 7, 2024 by
CPI
European Commission Extends Decision Deadline for Ita-Lufthansa Merger
May 7, 2024 by
CPI
UK, US and Australia Sanction Senior Leader of LockBit Cybercrime Gang
May 7, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Economics of Criminal Antitrust
Apr 19, 2024 by
CPI
Navigating Economic Expert Work in Criminal Antitrust Litigation
Apr 19, 2024 by
CPI
The Increased Importance of Economics in Cartel Cases
Apr 19, 2024 by
CPI
A Law and Economics Analysis of the Antitrust Treatment of Physician Collective Price Agreements
Apr 19, 2024 by
CPI
Information Exchange In Criminal Antitrust Cases: How Economic Testimony Can Tip The Scales
Apr 19, 2024 by
CPI